This study retrospectively analyzed patients with HER2-positive stage III/IV BC who were treated with pyrotinib-based regimens from October 2018 to October 2022 at the Affiliated Tumor Hospital of Guangxi Medical University. Here, ERBB2 is linked to breast cancer.